J&J’s Anti-Tau Asset Posdinemab Fails In Phase II Alzheimer’s Study

AC Immune-Partnered Tau Immunotherapy In Ongoing Trial

 
• By Mandy Jackson
  
Multiple agents are in development targeting tau tangles in Alzheimer's patients' brains (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

More from Clinical Trials